Screener
Iovance Biotherapeutics, Inc. IOVA Restricted Cash
Restricted Cash at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashNoncurrent.
The source filing: Iovance Biotherapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 9:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091716
FAQ
- What is Iovance Biotherapeutics, Inc.'s restricted cash?
- Iovance Biotherapeutics, Inc. (IOVA) reported restricted cash of $6.01M in Q2 2026.
- How has Iovance Biotherapeutics, Inc.'s restricted cash changed year-over-year?
- Iovance Biotherapeutics, Inc.'s restricted cash increased by 1.0% year-over-year, from $5.94M to $6.01M.
- What is the long-term trend for Iovance Biotherapeutics, Inc.'s restricted cash?
- Over 5 years (2020 to 2025), Iovance Biotherapeutics, Inc.'s restricted cash has grown at a 1.6% compound annual growth rate (CAGR), from $5.53M to $5.98M.
- What does restricted cash mean?
- Cash restricted for specific purposes by contractual, regulatory, or legal requirements — not available for general corporate use.
Ask your AI about Iovance Biotherapeutics, Inc.'s restricted cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude